Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
SKAN Group AG (SKAN.SW)
Allschwil, CH
SKAN Group AG is a global leader specializing in critical solutions for the pharmaceutical and chemical sectors, offering advanced isolators, cleanroom technologies, and decontamination processes across Asia, Europe, and the Americas. The company operates through two distinct divisions: Equipment and Solutions (E&S), and Services and Consumables (S&C). Its E&S segment delivers essential products for pharmaceutical manufacturing, including high-tech isolators, integrated automated systems, aseptic filling solutions, and specialized laboratory and cleanroom equipment. Meanwhile, the S&C segment focuses on providing comprehensive life cycle support, ready-to-use consumables, and custom digital and client-specific solutions. Founded in 1968, the company, which changed its name from BV Holding AG to SKAN Group AG in October 2021, is headquartered in Allschwil, Switzerland.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -4.98% | +4.31% | +8.77% | -5.16% | +0.71% | -4.98% | -31.68% | -37.53% | -34.06% | -34.06% | -34.06% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 2 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Instruments & Supplies: +7.9%-7.7% Q4'25: +10.3% (vs Q4'23)
-
EPS growth Medical - Instruments & Supplies: +16.3%-58.4% Q4'25: +36.6% (vs Q4'23)
-
FCF margin FCF growth · Medical - Instruments & Supplies: +27.1%+21.9% ★ Q4'25: +9.2% (vs Q4'23)
-
EBIT margin Medical - Instruments & Supplies: +13.5%+6.9% Q4'25: +16.7% (vs Q4'23)
-
ROIC Medical - Instruments & Supplies: +6.0%+11.4% ★ Q4'25: +73.4% (vs Q4'23)
-
Share dilution Medical - Instruments & Supplies: +0.1%+0.0% Q4'25: +0.0% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Instruments & Supplies: -0.24×3.65× Q4'25: 0.81× (vs Q4'23)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 2 Rev. Ana. 2 EPS Ana. |
Dec 2027 2 Rev. Ana. 2 EPS Ana. |
Dec 2028 2 Rev. Ana. 2 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
234.27M
est: 229.41M (+2.1%)
|
276.96M
est: 276.17M (+0.3%)
|
320.02M
est: 344.01M (-7.0%)
|
361.30M
est: 366.11M (-1.3%)
|
333.34M
est: 331.23M (+0.6%)
|
392.90M
390.00M – 395.80M
+18.6% YoY
|
456.25M
453.00M – 459.50M
+16.1% YoY
|
534.61M
534.61M – 534.61M
+17.2% YoY
|
609.30M
604.89M – 613.71M
+14.0% YoY
|
| EBITDA |
32.38M
est: 31.71M (+2.1%)
|
40.15M
est: 38.17M (+5.2%)
|
50.14M
est: 49.07M (+2.2%)
|
59.68M
est: 52.22M (+14.3%)
|
36.03M
est: 47.25M (-23.7%)
|
56.04M
55.63M – 56.46M
+18.6% YoY
|
65.08M
64.61M – 65.54M
+16.1% YoY
|
76.25M
76.25M – 76.25M
+17.2% YoY
|
86.91M
86.28M – 87.54M
+14.0% YoY
|
| EBIT |
24.86M
est: 23.70M (+4.9%)
|
29.46M
est: 28.53M (+3.3%)
|
37.75M
est: 36.41M (+3.7%)
|
47.20M
est: 38.75M (+21.8%)
|
22.86M
est: 35.06M (-34.8%)
|
41.59M
41.28M – 41.90M
+18.6% YoY
|
48.29M
47.95M – 48.64M
+16.1% YoY
|
56.59M
56.59M – 56.59M
+17.2% YoY
|
64.50M
64.03M – 64.96M
+14.0% YoY
|
| Net Income |
10.62M
est: 20.06M (-47.1%)
|
18.99M
est: 21.44M (-11.4%)
|
26.31M
est: 32.24M (-18.4%)
|
38.80M
est: 35.95M (+7.9%)
|
16.27M
est: 16.27M (+0.0%)
|
30.43M
26.08M – 34.87M
+87.0% YoY
|
39.94M
37.10M – 42.69M
+31.3% YoY
|
53.24M
49.24M – 57.38M
+33.3% YoY
|
62.28M
61.69M – 62.87M
+17.0% YoY
|
| SGA |
13.51M
est: 31.78M (-57.5%)
|
12.10M
est: 38.25M (-68.4%)
|
158.84M
est: 44.09M (+260.3%)
|
15.56M
est: 46.92M (-66.8%)
|
—
est: 42.45M (-100.0%)
|
50.35M
49.98M – 50.72M
+18.6% YoY
|
58.47M
58.06M – 58.89M
+16.1% YoY
|
68.51M
68.51M – 68.51M
+17.2% YoY
|
78.09M
77.52M – 78.65M
+14.0% YoY
|
| EPS |
0.84
est: 0.89 (-5.8%)
|
0.84
est: 0.95 (-11.3%)
|
1.17
est: 1.43 (-18.4%)
|
1.73
est: 1.60 (+8.2%)
|
0.72
est: 0.81 (-10.7%)
|
1.36
1.16 – 1.55
+68.0% YoY
|
1.77
1.65 – 1.90
+30.9% YoY
|
2.37
2.19 – 2.55
+33.6% YoY
|
2.77
2.74 – 2.80
+16.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | B- | 2/5 | 3/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | B- | 3/5 | 4/5 | 4/5 | 4/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | B | 3/5 | 4/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | iShares International Developed Small Cap Value Factor ETF ISVL | 0.13% | 397.8K | 0.31% |
| 2 | iShares MSCI Europe Small-Cap ETF IEUS | 0.06% | 100.1K | 0.41% |
| 3 | Xtrackers MSCI Europe Small Cap UCITS ETF 1C XXSC.L | 0.06% | 1.89M | 0.30% |
| 4 | iShares Core SPI(R) ETF (CH) CHSPI.SW | 0.04% | 2.73M | 0.10% |
| 5 | Schwab International Small-Cap Equity ETF SCHC | 0.04% | 1.92M | 0.06% |
| 6 | Avantis International Small Cap Equity ETF AVDS | 0.02% | 79.3K | 0.30% |
| 7 | iShares International Small-Cap Equity Factor ETF ISCF | 0.02% | 159.4K | 0.24% |
| 8 | iShares Currency Hedged MSCI EAFE Small-Cap ETF HSCZ | 0.02% | 55.9K | 0.83% |
| 9 | iShares MSCI EAFE Small-Cap ETF SCZ | 0.02% | 3.37M | 0.40% |
| 10 | Vanguard FTSE All-World ex-US Small-Cap ETF VSS | 0.02% | 2.95M | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Thomas Huber | Executive Director | 862.6K | male |
| Jonas Greutert | Chief Executive Officer | — | male |
| Marina Hani | Chief People & Culture Officer | — | female |
| Martin E. Steegmuller | Chief Product Officer, Chief Officer Innovation & Chief Service Officer | — | male |
| Philippe Jerome | Chief Sales & Marketing Officer | — | male |
| Ralf Kramer | Chief Technology Officer | — | male |
| Burim Maraj | Chief Financial Officer | — | male |
| Thomas Zinn | Chief Officer of Aseptic Manufacturing Services | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for SKAN.SW
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
